Pulmonary Embolism Symposium (PERT 2017)

 

Pulmonary Embolism Symposium (PERT 2017)

Current Regulatory Environment and Potential FDA Role in Furthering the Goals of the PERT Consortium to Improve Outcomes for Patients with PE and VTE

By Pulmonary Embolism Symposium (PERT 2017)
By Pulmonary Embolism Symposium (PERT 2017)
11 views
October 16, 2017
Comments 0
Login to view comments. Click here to Login
Session 4: Anticoagulation
11:14

Current Regulatory Environment and Potential FDA Role in Furthering …

Pulmonary Embolism Symposium (PERT 2017)

11 views
11:46

DOACs and Other Heparin Alternatives

Pulmonary Embolism Symposium (PERT 2017)

R. Rosovsky

710 views
13:55

NOAC Reversal Agents - Our Early Experience

Pulmonary Embolism Symposium (PERT 2017)

G. Davis

635 views
10:12

Long Term Anticoagulation - How and For How Long?

Pulmonary Embolism Symposium (PERT 2017)

52 views
10:05

Panel Discussion - Q&A with the Experts from PERT 2017

Pulmonary Embolism Symposium (PERT 2017)

10 views